(1)
Lebwohl, M.; Lacour, J.-P.; Liljedahl, M.; Lynde, C.; M?rch, M. H.; Tha?i, D.; Warren, R. B. Safety of Long-Term Proactive Management With Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial. J of Skin 2020, 4, s31.